Literature DB >> 11753045

Preoperative galactose elimination capacity predicts complications and survival after hepatic resection.

Claudio A Redaelli1, Jean-François Dufour, Markus Wagner, Martin Schilling, Jürg Hüsler, Lukas Krähenbühl, Markus W Büchler, Jürg Reichen.   

Abstract

OBJECTIVE: To analyze a single center's 6-year experience with 258 consecutive patients undergoing major hepatic resection for primary or secondary malignancy of the liver, and to examine the predictive value of preoperative liver function assessment. SUMMARY BACKGROUND DATA: Despite the substantial improvements in diagnostic and surgical techniques that have made liver surgery a safer procedure, careful patient selection remains mandatory to achieve good results in patients with hepatic tumors.
METHODS: In this prospective study, 258 patients undergoing hepatic resection were enrolled: 111 for metastases, 78 for hepatocellular carcinoma (HCC), 21 for cholangiocellular carcinoma, and 48 for other primary hepatic tumors. One hundred fifty-eight patients underwent segment-oriented liver resection, including hemihepatectomies, and 100 had subsegmental resections. Thirty-two clinical and biochemical parameters were analyzed, including liver function assessment by the galactose elimination capacity (GEC) test, a measure of hepatic functional reserve, to predict postoperative (60-day) rates of death and complications and long-term survival. All variables were determined within 5 days before surgery. Data were subjected to univariate and multivariate analysis for two patient subgroups (HCC and non-HCC). The cutoffs for GEC in both groups were predefined. Long-term survival (>60 days) was subjected to Kaplan-Meier analysis and the Cox proportional hazard model.
RESULTS: In the entire group of 258 patients, a GEC less than 6 mg/min/kg was the only preoperative biochemical parameter that predicted postoperative complications and death by univariate and stepwise regression analysis. A GEC of more than 6 mg/min/kg was also significantly associated with longer survival. This predictive value could also be shown in the subgroup of 180 patients with tumors other than HCC. In the subgroup of 78 patients with HCC, a GEC less than 4 mg/min/kg predicted postoperative complications and death by univariate and stepwise regression analysis. Further, a GEC of more than 4 mg/min/kg was also associated with longer survival.
CONCLUSIONS: This prospective study establishes the preoperative determination of the hepatic reserve by GEC as a strong independent and valuable predictor for short- and long-term outcome in patients with primary and secondary hepatic tumors undergoing resection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11753045      PMCID: PMC1422398          DOI: 10.1097/00000658-200201000-00010

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  59 in total

1.  A study of prognostic factors for hepatic resection for colorectal metastases.

Authors:  M Taylor; J Forster; B Langer; B R Taylor; P D Greig; C Mahut
Journal:  Am J Surg       Date:  1997-06       Impact factor: 2.565

Review 2.  Surgery and portal hypertension.

Authors:  C G Child; J G Turcotte
Journal:  Major Probl Clin Surg       Date:  1964

3.  [Galactose elimination capacity, a reliable test for quantitative comprehension of the liver function].

Authors:  M Heri; J Bircher
Journal:  Schweiz Med Wochenschr       Date:  1971-05-22

4.  An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Authors:  Y Fong; R L Sun; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

5.  Determination of the hepatic elimination capacity (Lm) of galactose by single injection.

Authors:  N Tygstrup
Journal:  Scand J Clin Lab Invest Suppl       Date:  1966

6.  No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach.

Authors:  G Torzilli; M Makuuchi; K Inoue; T Takayama; Y Sakamoto; Y Sugawara; K Kubota; A Zucchi
Journal:  Arch Surg       Date:  1999-09

7.  Determinants of survival following hepatic resection for metastatic colorectal cancer.

Authors:  E A Bakalakos; J A Kim; D C Young; E W Martin
Journal:  World J Surg       Date:  1998-04       Impact factor: 3.352

8.  Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume.

Authors:  K Shirabe; M Shimada; T Gion; H Hasegawa; K Takenaka; T Utsunomiya; K Sugimachi
Journal:  J Am Coll Surg       Date:  1999-03       Impact factor: 6.113

9.  Hepatic resection for hepatocellular carcinoma. An audit of 343 patients.

Authors:  E C Lai; S T Fan; C M Lo; K M Chu; C L Liu; J Wong
Journal:  Ann Surg       Date:  1995-03       Impact factor: 12.969

10.  Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis.

Authors:  S T Fan; E C Lai; C M Lo; I O Ng; J Wong
Journal:  Arch Surg       Date:  1995-02
View more
  25 in total

Review 1.  Optimizing hepatectomy for hepatocellular carcinoma in Asia-patient selection and special considerations.

Authors:  Clarence Nicholas Kotewall; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-08

2.  Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease.

Authors:  Aksel Lange; Henning Grønbæk; Hendrik Vilstrup; Susanne Keiding
Journal:  Scand J Gastroenterol       Date:  2010-11-01       Impact factor: 2.423

3.  Increase in left liver lobe function after preoperative right portal vein embolisation assessed with gadolinium-EOB-DTPA MRI.

Authors:  Dominik Geisel; Lutz Lüdemann; Thomas Keuchel; Maciej Malinowski; Daniel Seehofer; Martin Stockmann; Bernd Hamm; Bernhard Gebauer; Timm Denecke
Journal:  Eur Radiol       Date:  2013-05-08       Impact factor: 5.315

Review 4.  Quantitative PET of liver functions.

Authors:  Susanne Keiding; Michael Sørensen; Kim Frisch; Lars C Gormsen; Ole Lajord Munk
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

5.  Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database.

Authors:  Ronnie T Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; Chi Ming Lam; Wai Key Yuen; Chun Yeung; John Wong
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

6.  Kinetics of liver function tests after a hepatectomy for colorectal liver metastases predict post-operative liver failure as defined by the International Study Group for Liver Surgery.

Authors:  Keith J Roberts; Kishore G S Bharathy; J Peter A Lodge
Journal:  HPB (Oxford)       Date:  2012-10-26       Impact factor: 3.647

Review 7.  Predictive factors of short term outcome after liver transplantation: A review.

Authors:  Giuliano Bolondi; Federico Mocchegiani; Roberto Montalti; Daniele Nicolini; Marco Vivarelli; Lesley De Pietri
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

8.  Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection.

Authors:  Wilmar de Graaf; Krijn P van Lienden; Sander Dinant; Joris J T H Roelofs; Olivier R C Busch; Dirk J Gouma; Roelof J Bennink; Thomas M van Gulik
Journal:  J Gastrointest Surg       Date:  2010-02       Impact factor: 3.452

9.  Model for end-stage liver disease (MELD) score, as a prognostic factor for post-operative morbidity and mortality in cirrhotic patients, undergoing hepatectomy for hepatocellular carcinoma.

Authors:  Spiros G Delis; Andreas Bakoyiannis; Ioannis Biliatis; Konstantinos Athanassiou; Nikos Tassopoulos; Christos Dervenis
Journal:  HPB (Oxford)       Date:  2009-06       Impact factor: 3.647

10.  Regional metabolic liver function measured in patients with cirrhosis by 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT.

Authors:  Michael Sørensen; Kasper S Mikkelsen; Kim Frisch; Gerda E Villadsen; Susanne Keiding
Journal:  J Hepatol       Date:  2013-01-20       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.